#USA #Newnan #DuraBloc™ #SuᐧPor® #Poriferous

Poriferous, LLC Secures Patent for DuraBloc™ Technology

Poriferous, LLC, an established leader in the manufacturing of craniomaxillofacial and patient-specific implants, has been granted a significant advancement with its DuraBloc™ technology patent. The U.S. Patent and Trademark Office officially issued Patent No. 12,653,677 on June 16, 2026, marking a notable milestone for the company.

This patent not only bolsters Poriferous’ impressive portfolio of proprietary technologies but also reinforces its position as a global innovator in healthcare solutions. With the DuraBloc™ technology, patients can expect enhanced access to premium craniomaxillofacial implants, which promises quicker and more affordable surgical options.

Poriferous’ SuᐧPor implants are crafted from biocompatible, porous polyethylene. This material's unique design provides an interconnecting pore structure that supports fibrovascular ingrowth and seamless integration with surrounding tissues, ensuring durable results. The company’s implants are customizable; they can be trimmed and shaped in sterile environments, making them easily adaptable during surgical procedures without the fear of damaging the material.

One of the noteworthy features of SuᐧPor implants is the Advanced Retained Shape Memory™. This exclusive property allows the implants to maintain their intended form even after manipulation, resulting in optimal outcomes for various surgical procedures including reconstructive and augmentation surgeries. The DuraBloc™ technology adds to this incredible array of features by introducing a specialized manufacturing process that delivers a unique dual-sided design. The DuraBloc™ implant boasts a smooth, nonporous underside alongside the porous structures commonly found in SuᐧPor implants, allowing for tissue integration while minimizing unwanted tissue adhesion.

In particular, the DuraBloc™ design represents a leap forward in ensuring patient comfort and recovery. It allows for a remarkably reduced flange profile of 50%, which translates to a more aesthetically pleasing complexion post-surgery—all without compromising the implants’ fixation strength.

Aaron Noble, CEO and Founder of Poriferous, elaborated on the innovation, stating, “We actively collaborate with surgeons to refine our extensive catalog of implants. Our newly patented DuraBloc™ technology provides a revolutionary solution to the evolving requests for implants that are not only efficient but also easier to remove. This innovation enhances tissue ingrowth while simplifying the removal process, yielding natural results for patients.”

As part of their commitment to patient safety, Poriferous also incorporates the option of infusing their implants with antibiotics during surgery. This extra precaution helps in mitigating the risk of potential infections while maximizing the body's immune response through continuous fibrovascular ingrowth.

As the field of craniomaxillofacial surgery continues to advance, Poriferous remains at the forefront, dedicated to transforming patient care with its innovative solutions. The DuraBloc™ technology exemplifies the company’s vision to enhance healthcare outcomes and provide life-changing implants to patients globally.

For further information about Poriferous and their cutting-edge patented technologies, visit Poriferous.com.

About Poriferous

Founded with a mission to transform surgical implants, Poriferous strives to deliver quality results to all individuals in need. Backed by extensive research and active collaboration with leading medical professionals, the company specializes in high-quality SuᐧPor implants that are designed for seamless tissue integration, stability, and long-term effectiveness. SuᐧPor implants have garnered global recognition among surgeons, playing a crucial role in helping patients reclaim their self-confidence, functionality, and quality of life.